1507930-57-5

1507930-57-5 structure

Name: Gap19 TFA
Chemical Name: Gap19
CAS Number: 1507930-57-5
Molecular Formula: C₅₅H₉₆N₁₄O₁₃
Molecular Weight: 1161.44
Catalog: Signaling Pathways Cytoskeleton Gap Junction Protein
Create Date: 2020-01-23 16:06:51
Modify Date: 2026-07-01 11:55:46
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial[1][2].

Name	Gap19
Synonyms	(2S,5S,8S,11S,14S,17S)-17-((2S,3S)-2-((S)-5-Amino-2-((S)-2,6-diaminohexanamido)-5-oxopentanamido)-3-methylpentanamido)-2,8,11-tris(4-aminobutyl)-5-benzyl-14-((S)-sec-butyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaicosane-1,20-dioic acid , Gap19 (2S,5S,8S,11S,14S,17S)-17-((2S,3S)-2-((S)-5-Amino-2-((S)-2,6-diaminohexanamido)-5-oxopentanamido)-3-methylpentanamido)-2,8,11-tris(4-aminobutyl)-5-benzyl-14-((S)-sec-butyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaicosane-1,20-dioic acid myocdial,Gap19,cytoplasmic,Cx40/pannexin-1,inhibit,Gap Junction Protein,C-terminus,Gap 19,hemichannel,Inhibitor,loop,Gap-19,Cx43,channels,connexin Gap19 ，S6946 KQIEIKKFK GAP19 Trifluoroacetate L-Lysine, L-lysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl

Description	Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Cytoskeleton >> Gap Junction Protein
Target	Cx43 Hemichannel[1]
In Vitro	Gap19 (250 μM; for 30 min ) decreases mitochondrial potassium uptake[1]. Gap19 (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells[2]. Gap19 (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes[2]. Gap19 (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo[2].
In Vivo	Gap19 (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth[2]. Animal Model: C57/BL6 mice[2] Dosage: 25 mg/kg Administration: IV; 10 min before ligation Result: Significantly reduced the infarct size by approximately one-fifth.
References	[1]. Boengler K, et al. Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol. 2013 Jun 6;4:73. [2]. Wang N, et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2013 Jan;108(1):309.